You are here: Industry Insights > Valneva

News List

Valneva Begins Manufacturing of Inactivated, Adjuvanted COVID-19 Vaccine, Completes Study Recruitment americanpharmaceuticalreview
February 05, 2021
Valneva has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine.
UK Secures 40 Million Doses of Valneva COVID-19 Vaccine contractpharma
February 02, 2021
The UK Government has exercised its option to order 40 million doses of Valneva SE’s inactivated, adjuvanted COVID-19 vaccine candidate for supply in 2022.
Valneva Begins COVID Vax Production to Optimize Potential Deliveries contractpharma
January 29, 2021
Valneva SE began production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in an effort to optimize the timeline for potential deliveries of the vaccine.
Valneva partners with Oxford Immunotec on T cell analysis for COVID-19 vaccine pharmatimes
January 15, 2021
Valneva has chosen UK-based diagnostics company Oxford Immunotec to perform T cell testing on participants receiving its COVID-19 vaccine candidate (VLA2001) in a Phase I/II study.
Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate worldpharmanews
January 14, 2021
Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its ...
Valneva initiates Phase 1/2 clinical study of inactivated, adjuvanted COVID-19 vaccine candidate worldpharmanews
December 17, 2020
Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva fast-tracks paediatric development of Lyme disease vaccine pharmatimes
December 08, 2020
French vaccine specialist Valneva has announced that it will accelerate the paediatric development of its Lyme disease vaccine candidate VLA15, which it is currently developing alongside pharma giant Pfizer.
Valneva bags positive phase II results for Lyme disease vaccine pharmatimes
October 22, 2020
French speciality vaccine company Valneva has announced initial positive results from its second phase II study of its Lyme disease vaccine candidate VLA15.
Valneva’s Chikungunya Vax Granted PRIME Designation contractpharma
October 22, 2020
Becomes the first company worldwide to advance a chikungunya vaccine candidate into Phase III.
Valneva inks €1.37bn Covid-19 vaccine supply deal with UK pharmaceutical-technology
September 16, 2020
Speciality vaccines developer Valneva has announced a partnership worth €1.37bn with the UK Government to supply its inactivated Covid-19 vaccine candidate, VLA2001.

Previous page 1 2 3 4 5 Next page